Chiusura precedente | 0,0500 |
Aperto | 0,1000 |
Denaro | 0,0000 |
Domanda | 0,1500 |
Prezzo d'esercizio | 2,50 |
Scadenza | 2024-08-16 |
Min-Max giorno | 0,1000 - 0,5500 |
Contratto - Min-Max | N/D |
Volume | |
Open Interest | 4 |
Reigin Zawadzki, chief people officer, Caribou Biosciences Caribou biosciences appoints Reigin Zawadzki as chief people officer. BERKELEY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Reigin Zawadzki to the newly created position of chief people officer. Ms. Zawadzki brings over 20 years of experience leading human resources in the biotechnology ind
BERKELEY, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences: Citi 18th Annual BioPharma Conference, Boston, MASeptember 6, 2023Wells Fargo Healthcare Conference, Boston, MASeptember 7, 2023, 8:00 am EDTMorgan Stanley 21st Annual Global Healthcare Conference, New York, NYSeptember 11, 2023Jefferies Cell & Gene
-- CB-010 ANTLER trial dose expansion enrolling second-line LBCL patients; plan to share FDA feedback by YE 2023 and report initial dose expansion data in H1 2024 -- -- CB-011 CaMMouflage Phase 1 trial enrollment continues in r/r MM -- -- CB-012 IND application submission for r/r AML planned for H2 2023 -- -- Received $25.0 million equity investment from Pfizer -- -- Closed upsized public offering including full exercise of underwriters’ option to purchase additional shares, delivering $134.6 mi